NET REVENUES FROM COLLABORATIONS - Schedule of Deferred Revenue (Details) - USD ($) $ in Thousands |
Dec. 31, 2025 |
Dec. 31, 2024 |
|---|---|---|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||
| Deferred revenue | $ 4,845 | $ 55,481 |
| Regeneron Pharmaceuticals | ||
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||
| Deferred revenue | 4,845 | 55,481 |
| Research Services Obligation | Regeneron Pharmaceuticals | ||
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||
| Deferred revenue | 4,845 | 41,156 |
| C5 License Obligation | Regeneron Pharmaceuticals | ||
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||
| Deferred revenue | 0 | 12,018 |
| Regeneron Technology Transfer Obligation | Regeneron Pharmaceuticals | ||
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||
| Deferred revenue | $ 0 | $ 2,307 |